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Background: Treatment of in-stent restenosis (ISR) for patients who failed the initial therapy with a drug-eluting stent (DES) is challenging. There 
are several therapeutic options for this condition, including repeat DES, brachytherapy (VBT) or conventional angioplasty (c-PCI), but the optimal 
treatment remains unclear. This study aimed to assess the predictors for recurrence of DES failure and clinical outcomes after a first DES failure.
Methods: From 2003 to 2007, 535 patients presenting with angiographic ISR after DES implantation were included. Of these, 396 patients 
completed 1-year follow-up. The composite endpoint of death, myocardial infarction, and target lesion revascularization (MACE) was systematically 
index at 1-year follow up.
Results: This population presents a high prevalence of co-morbidities, including diabetes (45.2%), chronic renal failure (19.8%) and congestive 
heart failure (17.2%). Patients were treated with new-DES implantation (n= 323), VBT (n= 123) and cPCI (n= 89). The rate of diffuse and proliferative 
restenosis (length >10 mm) was 49.3%. The overall incidence of recurrent DES failure at 1-year follow-up was 18.4 % (n=69). The rate of the 
composite MACE was 16.7% for re-DES, 19.1% for VBT, and 16.9% for cPCI (p=0.86). After adjustment using the traditionally known covariates 
related with ISR, none of the tested variables independently predicted occurrence of 1-year composite MACE.
Conclusions: Recurrence of ISR after DES treatment failure is not benign and remains challenging independent of the treatment modality. The 
absence of the traditional predictors for ISR in this population invokes the presence of unrecognized predisposed conditions.
